Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.5%. By the end of trading, Shire fell $1.43 (-1.0%) to $136.36 on light volume. Throughout the day, 258,904 shares of Shire exchanged hands as compared to its average daily volume of 445,800 shares. The stock ranged in price between $135.90-$136.75 after having opened the day at $136.12 as compared to the previous trading day's close of $137.79. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 39.9%,

Prima Biomed



), down 16.0%,




TheStreet Recommends

), down 9.5% and

Ariad Pharmaceuticals



), down 8.8%.

Shire plc, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $26.0 billion and is part of the health care sector. The company has a P/E ratio of 37.7, above the S&P 500 P/E ratio of 17.7. Shares are up 50.4% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Shire a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front,

Echo Therapeutics



), up 72.9%,




), up 29.8%,




), up 19.1% and




), up 13.2% , were all gainers within the drugs industry with

Isis Pharmaceuticals



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.